Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
309M
-
Number of holders
-
224
-
Total 13F shares, excl. options
-
296M
-
Shares change
-
-7.24M
-
Total reported value, excl. options
-
$3.6B
-
Value change
-
-$89.7M
-
Put/Call ratio
-
0.62
-
Number of buys
-
124
-
Number of sells
-
-82
-
Price
-
$12.16
Significant Holders of AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share (FOLD) as of Q3 2023
267 filings reported holding FOLD - AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share as of Q3 2023.
AMICUS THERAPEUTICS, INC. - Common Stock, par value $0.01 per share (FOLD) has 224 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 296M shares
of 309M outstanding shares and own 95.88% of the company stock.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (27.7M shares), Avoro Capital Advisors LLC (27.4M shares), VANGUARD GROUP INC (27.1M shares), BlackRock Inc. (20.9M shares), Redmile Group, LLC (16.9M shares), JANUS HENDERSON GROUP PLC (14.9M shares), JPMORGAN CHASE & CO (13M shares), STATE STREET CORP (11.4M shares), MORGAN STANLEY (10.7M shares), and Palo Alto Investors LP (10.5M shares).
This table shows the top 224 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.